- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ind-Swift Laboratories' Q3 FY26 saw revenue reach ₹177.06 Cr. Operating EBITDA grew 6.60% quarter-over-quarter to ₹9.11 Cr (5.95% margin), while Net Profit jumped 22.60% QoQ to ₹10.74 Cr (6.07% margin). This efficiency gain followed a historic strategic reset, including the ₹1,650 Cr divestment of its API & CRAMS business and a merger, making ISLL a net debt-free, pure-play formulations platform with a ₹550 Cr revenue base largely from exports.
Strategic focus includes strengthening CDMO visibility via an FY27 Viatris partnership and expanding Own-Brand presence in UAE and Central Asia with 400+ registered products. Management aims to double revenue to ₹1,200+ Cr by FY29, targeting 20-25% CAGR. The CDMO business is projected to triple to ₹550-600 Cr, with Viatris alone adding ₹200-220 Cr by FY27. They expect EBITDA margin expansion of 250-300 BPS, supported by high-margin segments and 400+ new dossier filings by FY27.